Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport in Benign Essential Blepharospasm
NCT00234507Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jan 2003
- Primary completion
- May 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abobotulinumtoxinA in benign essential blepharospasm (BEB) (4 arms), sponsored by Ipsen. Primary endpoint: Percentage of Normal Activity at 4 weeks. Started Jan 2003; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT00234507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234507.